Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis
Open Access
- 8 May 2017
- journal article
- review article
- Published by Springer Nature in Respiratory Research
- Vol. 18 (1) , 1-9
Abstract
Reducing rescue medication use is a guideline-defined goal of asthma treatment, however, little is known about the validity of rescue medicine use as a marker of symptoms in chronic obstructive pulmonary disease (COPD). To improve patient outcomes, greater insight is needed into the relationship between rescue medication use and alternative COPD outcomes. A systematic search of electronic databases (Embase®, MEDLINE® and Cochrane CENTRAL) was conducted from database start to 26 May, 2015. Studies of bronchodilator therapy with a duration of ≥24 weeks were included if they reported either mean change from baseline (CFB) in rescue medication use in puffs/day or % rescue-free days (%RFD), and at least one other COPD endpoint. Correlation and meta-regression analyses were undertaken to test the association between rescue medication use and other COPD outcomes using weighted means (weights proportional to the sample size of the treatment group) and unweighted means (equal weight for each treatment group). Each association was assessed at 6 months and study end. Forty-six studies involving 46,531 patients provided mean data from 145 treatment groups for evaluation. Changes in both measures of rescue medication use were correlated with changes in trough forced expiratory volume in one second ([FEV1]; Pearson correlation coefficients |r| ≥ 0.63; p < 0.0001) and with St George’s Respiratory Questionnaire (SGRQ) score (|r| ≥ 0.70; p < 0.0001) at study end. Change in rescue medication use in puffs/day during the study correlated with annualized rates of moderate/severe exacerbations at 6 months and study end (both r = 0.66; p ≤ 0.0028). CFB in puffs/day was not well correlated with Transition Dyspnoea Index (TDI), but %RFD did correlate with TDI score at 6 months and study end (both r = 0.69; p < 0.0001). The values for CFB in puffs/day corresponding to the proposed minimal clinically important differences for trough FEV1 and SGRQ score were -1.3 and -0.6 puffs/day, respectively. A -1.0 puffs/day CFB in rescue use corresponded to a change of 0.26 events/patient-year in moderate/severe exacerbations. This analysis provides clear evidence of associations at a patient group level between rescue medication use and other clinically important COPD outcomes.Keywords
Funding Information
- GSK
This publication has 15 references indexed in Scilit:
- Relationship Between FEV1 and Patient-Reported Outcomes Changes: Results of a Meta-Analysis of Randomized Trials in Stable COPDChronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, 2016
- Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary diseaseBMC Pulmonary Medicine, 2015
- Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group studyThe Lancet Respiratory Medicine, 2013
- Health status in the TORCH study of COPD: treatment efficacy and other determinants of changeRespiratory Research, 2011
- Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic reviewRespiratory Research, 2011
- Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysisRespiratory Research, 2011
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- St. George's Respiratory Questionnaire: MCIDCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2005
- Minimal Clinically Important Differences in COPD Lung FunctionCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2005
- Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEuropean Respiratory Journal, 2004